Key Capital Corporation Announces Immunotherapy Product Rights Agreement – Yahoo Finance
|
Key Capital Corporation Announces Immunotherapy Product Rights Agreement
Yahoo Finance The Immunitor V-5 immunotherapy product has recently demonstrated groundbreaking trial success in the treatment of patients with advanced or terminal liver cancer (Hepatocellular Carcinoma or HCC). V-5 is not USA FDA approved at this time, and is … |
